Table 1 Characteristics of included studies in the meta-analysis
| Â | Author | Year | Region | Age | Sample type | case/control(n=) | Control type | Histological type | Screening method | TP | FP | FN | TN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Zheng, Z.G. | 2014 | China | 55 | Serum | 34/36 | Benign | High-grade-serous ovarian cancer | MB-WCX | 18 | 7 | 16 | 29 |
2 | Wu, S | 2012 | China | 48.4 | Serum | 25/30 | Health and benign | EOC | MB-WCX | 22 | 5 | 3 | 25 |
3 | Swiatly (a) | 2017 | Poland | 65 | Serum | 11/12 | Bilateral salpingo-oophorectomy | OC | C18 ZipTip | 8 | 4 | 3 | 8 |
4 | Swiatly (b) | 2017 | Poland | 65 | Serum | 11/12 | Bilateral salpingo-oophorectomy | OC | C18 ZipTip | 9 | 6 | 2 | 6 |
5 | Swiatly (c) | 2017 | Poland | 65 | Serum | 11/12 | Bilateral salpingo-oophorectomy | OC | C18 ZipTip | 0 | 6 | 1 | 6 |
6 | Periyasamy(a) | 2015 | India | 51 | Plasma | 39/149 | Health | Serous epithelial ovarian cancer | MB-HIC C8 | 33 | 33 | 6 | 116 |
7 | Periyasamy(b) | 2015 | India | 51 | Plasma | 39/149 | Health | Serous epithelial ovarian cancer | MB-HIC C8 | 34 | 48 | 5 | 101 |
8 | Periyasamy(c) | 2015 | India | 51 | Plasma | 39/149 | Health | Serous epithelial ovarian cancer | MB-HIC C8 | 36 | 58 | 3 | 91 |
9 | Periyasamy(d) | 2015 | India | 51 | Plasma | 39/149 | Health | Serous epithelial ovarian cancer | MB-WCX | 30 | 32 | 9 | 117 |
10 | Periyasamy(e) | 2015 | India | 51 | Plasma | 39/149 | Health | Serous epithelial ovarian cancer | MB-WCX | 35 | 45 | 4 | 104 |
11 | Periyasamy(f) | 2015 | India | 51 | Plasma | 39/149 | Health | Serous epithelial ovarian cancer | MB-WCX | 27 | 38 | 12 | 111 |
12 | Periyasamy(g) | 2015 | India | 51 | Plasma | 24/124 | Health | Serous epithelial ovarian cancer | IMAC-Cu MBs | 19 | 25 | 5 | 99 |
13 | Periyasamy(h) | 2015 | India | 51 | Plasma | 24/124 | Health | Serous epithelial ovarian cancer | IMAC-Cu MBs | 21 | 50 | 3 | 74 |
14 | Periyasamy(i) | 2015 | India | 51 | Plasma | 24/124 | Health | Serous epithelial ovarian cancer | IMAC-Cu MBs | 19 | 46 | 5 | 78 |
15 | John F. (a) | 2010 | UK | 61.8 | Serum | 39/22 | Benign | OC | C18 ZipTip | 24 | 6 | 15 | 16 |
16 | John F. (b) | 2010 | UK | 61.8 | Serum | 39/66 | Health | OC | C18 ZipTip | 18 | 7 | 21 | 59 |
17 | Lee, J. H. | 2016 | South Korea | 55.5 | Serum | 29/24 | Benign | OC | NA | 26 | 0 | 3 | 24 |
18 | Ali Tiss | 2010 | UK | NA | Serum | 23/29 | Benign | OC of CA125 > 30 U/mL | C18 ZipTip | 16 | 4 | 7 | 25 |